320 211

Cited 9 times in

Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.

Authors
 Hyung Suk Kim  ;  Ja Hyeon Ku  ;  Se Joong Kim  ;  Sung Joon Hong  ;  Sung Hoo Hong  ;  Hong Sup Kim  ;  Tae Gyun Kwon  ;  Jin Seon Cho  ;  Seong Soo Jeon  ;  Kwan Joong Joo  ;  Han Jong Ahn  ;  Hong Seok Park  ;  Do Hwan Seong  ;  Dong Deuk Kwon  ;  Hyung Jin Kim  ;  Jae Sung Lim  ;  Hyung-Lae Lee 
Citation
 YONSEI MEDICAL JOURNAL, Vol.57(4) : 855-864, 2016 
Journal Title
 YONSEI MEDICAL JOURNAL 
ISSN
 0513-5796 
Issue Date
2016
MeSH
Aged ; Carcinoma in Situ/mortality* ; Carcinoma in Situ/pathology* ; Carcinoma in Situ/therapy ; Disease Progression ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality* ; Neoplasm Recurrence, Local/pathology* ; Prognosis ; Proportional Hazards Models ; Republic of Korea ; Retrospective Studies ; Risk ; Urinary Bladder Neoplasms/mortality* ; Urinary Bladder Neoplasms/pathology* ; Urinary Bladder Neoplasms/therapy
Keywords
Urinary bladder neoplasm ; disease progression ; prognosis ; recurrence
Abstract
PURPOSE: To identify the prognostic factors related to tumor recurrence and progression in Korean patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data were collected and analyzed for 2412 NMIBC patients from 15 centers who were initially diagnosed after transurethral resection of bladder tumor (TURBT) from January 2006 to December 2010. Using univariable and multivariable Cox proportional hazards models, the prognostic value of each variable was evaluated for the time to first recurrence and progression. RESULTS: With a median follow-up duration of 37 months, 866 patients (35.9%) experienced recurrence, and 137 (5.7%) experienced progression. Patients with recurrence had a median time to the first recurrence of 10 months. Multivariable analysis conducted in all patients revealed that preoperative positive urine cytology (PUC) was independently associated with worse recurrence-free survival [RFS; hazard ratio (HR) 1.56; p<0.001], and progression-free survival (PFS; HR 1.56; p=0.037). In particular, on multivariable analysis conducted for the high-risk group (T1 tumor/high-grade Ta tumor/carcinoma in situ), preoperative PUC was an independent predictor of worse RFS (HR 1.73; p<0.001) and PFS (HR 1.96; p=0.006). On multivariable analysis in patients with T1 high-grade (T1HG) cancer (n=684), better RFS (HR 0.75; p=0.033) and PFS (HR 0.33; p<0.001) were observed in association with the administration of intravesical Bacillus Calmette-Guérin (BCG) induction therapy. CONCLUSION: A preoperative PUC result may adversely affect RFS and PFS, particularly in high-risk NMIBC patients. Of particular note, intravesical BCG induction therapy should be administered as an adjunct to TURBT in order to improve RFS and PFS in patients with T1HG cancer.
Files in This Item:
T201602034.pdf Download
DOI
10.3349/ymj.2016.57.4.855
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Hong, Sung Joon(홍성준) ORCID logo https://orcid.org/0000-0001-9869-065X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/147058
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links